glp-1 obesity drug news today september 2025 Alarming rise in weight loss overdoses A network meta-analysis backed weight-loss

Studies show that estrogen therapy during menopause can attenuate visceral fat gain by as much as 60%, improve insulin sensitivity, and even help increase lean muscle mass

As GLP-1 agonists have garnered attention for management of obesity due to their effect on reducing insulin sensitivity, they are now being considered a therapeutic option for the treatment of PCOS (polycystic ovarian syndrome), one of the most common causes of subfertility, diagnosed via Rotterdams criteria: oligomenorrhea, hyperandrogenism and polycystic ovaries (97)

Will my health insurance cover the cost

Finally, agent selection is influenced by insurance formulary and cost

It is a GLP-1 receptor agonist , a medication that works by binding to GLP-1 receptors in the body

Geller, G